View profile

FarmaKology-Promising anti-cancer treatment discovered in sea squirts

Revue
 
 

FarmaKology

December 27 · Issue #90 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".


Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+13K Subscribers )!

 FarmaKology-Promising anti-cancer treatment discovered in sea squirts
FarmaKology-Promising anti-cancer treatment discovered in sea squirts
Novo Banking
Novo Banking
Today's Company
Acticor Biotech
Acticor Biotech
Acticor Biotech 
Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), which is developing an innovative “first in-class” treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.
News
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Taiwan. STRO-002 is a FolRα-targeting antibody-drug conjugate , currently in clinical studies for patients with ovarian and endometrial cancers in the U.S. and Europe.
In a recent revelation, experts have said that antiviral pills against Covid, may not be safe for everyone. After doctors and pharmacists closely analysed the pills, they concluded that these pills can be life-threatening when taken with other medications. The Food and Drug Administration (FDA), recently gave heads up to two pills - Pfizer’s Paxlovid and Merck’s Molnupiravair.  Paxlovid’s treatment is a combination of two pills taken over five days. It has been authorised for mild to moderate Covid in people as young as 12 years, who have underlying conditions that increase the risk of hospitalisation and death from the coronavirus. 
I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation of China’s National Medical Products Administration has approved I-Mab’s IND submission for the initiation of a phase 2 trial in China for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda®) in patients with solid tumors, including non-small cell lung cancer , urothelial carcinoma, and other selected cancers. I-Mab has acquired exclusive rights to develop and commercialize enoblituzumab in Greater China from MacroGenics.
 Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Swiss Federal Government has exercised its option to purchase an additional seven million doses of Moderna’s booster vaccine for delivery in the second half of 2022. These doses are in addition to the initial seven million doses of booster vaccine the Swiss Federal Government agreed to purchase for delivery in 2022 and brings Switzerland’s order commitment to a total of 27.5 million doses.
Spend $1 Today, Save up to $2k on Your Next Vacay with Dollar Flight Club.
Research & Study
Podcast
Stream episode Looking back on the first year of 'First Opinion Podcast' by First Opinion Podcast podcast | Listen online for free on SoundCloud
Job Opportunities
Upcoming Webinar
A Collaborative Approach to Complex Chemistry
Video
What does new COVID cases mean now? | The age of Omicron, End game? | Changing mind set on new cases
Anycart
Anycart
FarmaKology
FarmaKology
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue